|
|
| | PTC-209 (hydrobroMide) Basic information |
| Product Name: | PTC-209 (hydrobroMide) | | Synonyms: | PTC-209 (hydrobroMide);PTC-209HBR;2-Thiazolamine, N-(2,6-dibromo-4-methoxyphenyl)-4-(2-methylimidazo[1,2-a]pyrimidin-3-yl)-, hydrobromide;CS-1314;N-(2,6-dibromo-4-methoxyphenyl)-4-(2-methylimidazo[1,2-a]pyrimidin-3-yl)-1,3-thiazol-2-amine;PTC-209 HBr ，S7539 | | CAS: | 1217022-63-3 | | MF: | C17H14Br3N5OS | | MW: | 576.10296 | | EINECS: | | | Product Categories: | Inhibitors | | Mol File: | 1217022-63-3.mol |  |
| | PTC-209 (hydrobroMide) Chemical Properties |
| storage temp. | Store at -20°C | | solubility | ≥ 22.9mg/mL in DMSO with gentle warming | | form | Solid | | color | Light yellow to yellow |
| | PTC-209 (hydrobroMide) Usage And Synthesis |
| Uses | PTC-209 is a potent and selective BMI-1 inhibitor. It results in irreversible reduction of cancer-initiating cells (CICs). | | in vivo | PTC-209 (60 mg/kg body weight; subcutaneously; once a day for 11 days) significantly reduces tumor volume[2]. | Animal Model: | Nude mice (male, aged 8-10 weeks, HCT1116 cell-derived tumor)[1] | | Dosage: | 60 mg/kg body weight | | Administration: | Subcutaneously; once a day for 11 days | | Result: | Significantly reduced tumor volume.
|
|
| | PTC-209 (hydrobroMide) Preparation Products And Raw materials |
|